Novartis India Reports Q1 FY27 Net Profit Up 16.6% YoY to ₹322.1 Million; Revenue Rises 18.6% to ₹1,038.1 Million

Pharmaceutical major Novartis India Limited (BSE: 500672) today announced its unaudited financial results for the first quarter of Financial Year 2026-2027 (Q1 FY27) ended June 30, 2026.

The company posted double-digit top-line and bottom-line growth, driven by an expansion in operations revenue and sustained demand across its core commercial product lines.

Executive Financial Highlights

Revenue from Operations: Crossed the ₹100-crore mark to reach ₹1,038.1 million (₹103.81 crore) for Q1 FY27, registering an 18.57% YoY growth compared to ₹875.5 million in Q1 FY26 and a 14.64% QoQ surge over ₹905.5 million in Q4 FY26.

Total Income: Reached ₹1,125.5 million, supported by ₹87.4 million in other income, up from ₹981.6 million in Q1 FY26.

Profit Before Tax (PBT): Came in at ₹431.7 million, reflecting a 15.99% YoY increase compared to ₹372.2 million in Q1 FY26 and a 43.23% QoQ surge over ₹301.4 million in Q4 FY26.

Net Profit After Tax (PAT): Net profit for the period expanded by 16.62% YoY to ₹322.1 million (₹32.21 crore), up from ₹276.2 million in Q1 FY26 and 27.56% QoQ compared to ₹252.5 million in Q4 FY26.

Total Comprehensive Income: Stood at ₹322.1 million for Q1 FY27.

Earnings Per Share (EPS): Basic and diluted EPS for the quarter rose to ₹13.05 per share (face value of ₹5/- each, not annualised), up from ₹11.19 in Q1 FY26 and ₹10.23 in Q4 FY26.

Operational Expense Summary

Total expenses for Q1 FY27 came in at ₹693.8 million, compared to ₹609.4 million in Q1 FY26 and ₹704.2 million in Q4 FY26.

Purchases of Stock-in-Trade: Stood at ₹760.5 million, compared to ₹473.9 million in Q1 FY26 and ₹683.4 million in Q4 FY26.

Changes in Inventories of Stock-in-Trade: Reflected a credit of ₹(203.8) million.

Employee Benefits Expense: Controlled at ₹47.2 million, down from ₹52.9 million in Q1 FY26.

Other Expenses: Accounted for ₹84.8 million, down sequentially from ₹134.7 million in Q4 FY26.

Depreciation & Finance Costs: Remained stable at ₹4.2 million and ₹0.6 million, respectively.

Tax Expense: Total tax expense for Q1 FY27 stood at ₹109.6 million, which included current tax of ₹114.6 million and a deferred tax credit of ₹(5.0) million.

Equity & Capital Structure

The paid-up equity share capital of Novartis India Limited remained unchanged at ₹123.4 million (comprising equity shares with a face value of ₹5/- each) as of June 30, 2026. Other equity for the full year ended March 31, 2026, stood at ₹8,054.9 million.

Shares of Novartis India Limited was last trading in BSE at Rs. 1668.95 as compared to the previous close of Rs. 1699.05. The total number of shares traded during the day was 13782 in over 1337 trades.

The stock hit an intraday high of Rs. 1777.50 and intraday low of 1640.00. The net turnover during the day was Rs. 23484717.00.